TL;DR
A pharmaceutical company reportedly turned to TissUse after the U.S. FDA declined a clinical-trial application supported by animal data and asked for organ-on-a-chip data or a comparable alternative. The episode points to growing interest in nonanimal methods, but broad adoption still depends on validation, policy changes and training.
A pharmaceutical company recently approached German biotech firm TissUse after the U.S. Food and Drug Administration declined permission for a clinical trial supported by animal data, according to TissUse executive and researcher Ilka Maschmeyer. She said the agency wanted data from organs-on-chips or a comparable alternative, a sign that methods designed to model human biology without animal tests are beginning to attract regulatory attention.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Organs-on-chips use small devices with channels lined by human cells to reproduce selected functions of organs. The technology’s early landmark example was a lung model developed by cell biologist Donald Ingber and colleagues at Harvard University’s Wyss Institute. Described in a paper submitted to Science 17 years before the IEEE Spectrum report, the device used air pressure to make its cell-lined channels expand and contract, mimicking a lung’s breathing motion.
The team reported that the model responded to inflammatory proteins and bacteria in ways resembling living lungs. Tests with silica nanoparticles also indicated that the movement of the tissue affected how it absorbed particles. Science’s editors initially asked the researchers to compare results with mouse experiments; the team added those tests, and the paper was published in 2010. IEEE Spectrum reported that it has since been cited by nearly 5,400 papers.
TissUse builds organ-on-a-chip systems for pharmaceutical research. Maschmeyer told IEEE Spectrum that companies seeking such systems are still unusual, but she expects requests to become more common. These technologies are part of a wider group called new approach methodologies, or NAMs. The report says these include approaches that are not yet rigorously tested across the board, and it does not provide detailed documentation of the drug application or the FDA’s decision.
Regulators Are Asking for Human-Based Data
The reported application matters because it suggests that nonanimal evidence may be considered not only as a research tool but also as part of the information regulators want to review before a clinical trial. If that approach becomes more frequent, drug developers may have stronger reasons to invest in methods that reproduce aspects of human biology, rather than relying only on animal studies.
That does not establish that organs-on-a-chip can replace animal testing across drug development. The report describes one company’s account and does not identify the medicine, the application date, or the precise regulatory correspondence. Still, the episode illustrates how expectations may be shifting: a method once treated as an experimental complement could, in some cases, be requested as relevant evidence.
The stakes include both patient safety and the quality of early drug decisions. The report notes that about 92 percent of drugs entering U.S. clinical trials fail to reach the market, for reasons that include commercial decisions as well as safety and effectiveness problems. That statistic does not show that animal testing causes those failures. It does underscore why researchers are exploring whether human-cell-based models can better predict some outcomes, while recognizing that disease complexity and study design also shape results.
Products Worth Considering

Levoit Vital 100S-P Air Purifier for Home and Pets

Withings BPM Vision Blood Pressure Monitor

Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Whitestone
As an affiliate, we earn on qualifying purchases.
From Lung Chip to Drug Research
When Ingber’s team first presented its lung model, the editors’ request for mouse comparisons reflected the prevailing expectation that a new model should be checked against animal results. The researchers conducted the requested experiments before publication. The paper’s reception helped establish the device as a proof of principle, but publication and citation counts do not by themselves establish that a model is sufficiently reliable for every regulatory or clinical use.
Since then, researchers have developed a range of NAMs, including organ-on-a-chip systems that place human tissues in microfluidic devices. These can model interactions between tissues and organs in ways that static cell cultures cannot. The report describes NAMs as a diverse category, with names that vary across the field, and says early studies show potential while many methods still need rigorous testing.
The central challenge has consequently moved beyond building more complex devices. Researchers and regulators need ways to validate and standardize them, including head-to-head comparisons with animal experiments. Their use also depends on practical changes: policy, researcher training and institutional culture all affect whether a technically promising tool becomes part of routine drug development.
Validation and FDA Details Remain Open
The report does not name the pharmaceutical company or drug, give the date of the FDA decision, or reproduce the agency’s request. It is therefore unclear exactly what evidence the company submitted, whether the FDA formally required organ-on-a-chip data for this application, or whether it could satisfy the request with another type of nonanimal method.
More broadly, the reliability and regulatory standing of specific NAMs remain unsettled. The source says many methods have not yet been rigorously tested and describes validation—standardized procedures and comparisons with animal studies—as a major obstacle. It does not establish that these approaches can replace animal models for all drugs, organs or safety questions.
Standardization Will Shape Wider Use
The next steps described in the report are method validation, standardization and direct comparisons with existing animal experiments. Regulators, researchers and drug companies will also need to establish how NAM results should be submitted and interpreted, and prepare staff to work with the systems.
For the specific drug application, IEEE Spectrum’s account does not say whether the company later supplied the requested data or whether the FDA authorized a trial. The broader measure of progress will be whether independently tested methods are adopted in repeatable ways, and whether regulators accept them for clearly defined uses. Until those details emerge, the reported case is evidence of growing interest, not proof of a wholesale change in drug testing.
Key Questions
What are organ-on-a-chip systems?
They are small devices with channels lined by living cells, often human cells, designed to reproduce selected organ functions. Some systems use fluid flow or movement to model how tissues behave.
Did the FDA ban animal testing in this case?
No such ban is described. According to TissUse executive Ilka Maschmeyer, the agency wanted organ-on-a-chip data or a comparable alternative for a drug application supported by animal data. The report does not provide the FDA’s written decision or specify the alternative evidence it would accept.
Can these methods replace animal studies for every drug?
The report does not establish that. It says NAMs show potential, but many methods still need rigorous testing and validation. Their suitability may depend on the drug and the biological question being studied.
Why is validation a barrier?
Researchers and regulators need standardized procedures and comparisons that show when a method produces reliable, useful results. The report also identifies policy, training and institutional culture as barriers to broader implementation.
Source: hn
